Gilead halts enrollment in solid tumor trials
16 Feb 2024
Phase 2AcquisitionImmunotherapy
Gilead Sciences has halted enrollment globally in its magrolimab solid tumor studies.
The decision follows a request from the FDA for a partial clinical hold on the trials. The FDA's request comes on the heels of a previous full clinical hold on all magrolimab studies in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), following reports of increased death risk.
Magrolimab, a monoclonal antibody, is undergoing clinical development for the treatment of various cancers, including myelodysplastic syndrome, acute myeloid leukemia, and diffuse large B-cell lymphoma, where there is a pressing need for innovative treatments. Magrolimab holds the potential to become a first-in-class therapy.
The impacted studies include phase 2 trials in head and neck squamous cell carcinoma, solid tumors, triple-negative breast cancer, and colorectal cancer. Patients already enrolled in Gilead's ELEVATE solid tumor studies and experiencing clinical benefits may opt to continue receiving magrolimab after reconsenting with their healthcare provider.
In its statement, Gilead warned of uncertainties surrounding the progression and completion of clinical trials, potential regulatory hurdles, and the possibility of discontinuing magrolimab development.
Gilead got its hands on magrolimab via its 2020 acquisition of cancer drug developer Forty Seven for $4.9 billion in cash. Forty Seven, headquartered in California, was a clinical-stage immuno-oncology company with a focus on developing novel checkpoint therapies to activate macrophages and combat cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.